2011;S4:001. 60. Osada T, Yang XY, Hart man ZC, Glass O, Hodges BL, Niedzwiecki D, et al. Optimization of vaccine responses with an E1, E2b and E3 -deleted Ad5 vector circumvents pre - existing anti -vector immunity. Cancer Gene Ther. 2009;16(9):673 -82. 61. Gabitzsch ES, Xu Y, Balint Jr JP, Hartman ZC, Lyerly HK, Jones FR. Anti -tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1 -, E2b - ]-CEA. Cancer Immunol Immunother. 2010;59(7):1131 -5. 62. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A, et al. A preliminary and comparative evaluation of a novel Ad5 [E1 -, E2b -] recombinant -based vaccine used to induce cell mediated immune responses. Immunol Lett. 2009;122(1):44 -51. 63.